Fulcrum Therapeutics (NASDAQ:FULC – Get Free Report) is expected to issue its Q3 2026 results before the market opens on Thursday, October 29th. Analysts expect Fulcrum Therapeutics to post earnings of ($0.0745) per share for the quarter. Parties can find conference call details on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 7:00 AM ET.
Fulcrum Therapeutics (NASDAQ:FULC – Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.10). On average, analysts expect Fulcrum Therapeutics to post ($0.60) EPS for the current fiscal year and ($0.12) EPS for the next fiscal year.
Fulcrum Therapeutics Price Performance
FULC opened at $3.70 on Wednesday. The firm has a 50 day simple moving average of $3.77 and a 200 day simple moving average of $5.99. Fulcrum Therapeutics has a fifty-two week low of $2.83 and a fifty-two week high of $15.74.
Analyst Ratings Changes
Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Fulcrum Therapeutics in a report on Thursday, October 15th. One analyst has rated the stock with a Buy rating, seven have assigned a Hold rating and four have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Reduce” and an average target price of $8.20.
Check Out Our Latest Research Report on Fulcrum Therapeutics
Fulcrum Therapeutics Company Profile
Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for genetically driven diseases. The company’s research approach is based on selectively modulating gene expression to address the underlying biology of disease rather than targeting individual symptoms.
Fulcrum’s lead investigational program is losmapimod, an oral small-molecule therapy being developed for facioscapulohumeral muscular dystrophy (FSHD), a rare and progressive genetic muscle disorder.
Read More
- Five stocks we like better than Fulcrum Therapeutics
- Coca-Cola Stock Is Everything AI Isn’t—And That’s Its Biggest Strength
- Apple’s Foldable iPhone Sold Out in Minutes, But Wall Street Has Questions
- Netflix Is Making Big Changes, But Can It Fix What’s Really Hurting Growth?
- Charging Ahead: Solid Power’s Pilot Line Leaves the Lab
Receive News & Ratings for Fulcrum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulcrum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
